Press Release on Q1FY27 Business and Financial Performance
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 01 Aug 2026, 05:16 PM IST · BSE ID: 8987b651-a6df-48ea-a903-b205d879c387
View Original BSE Filing (PDF)
💡
In Simple Terms
Aarti Drugs reported higher sales in Q1 FY27, but profit was lower due to a tax refund in the previous year's quarter.
🤖 AI Summary
- Aarti Drugs' Q1 FY27 consolidated revenue reached Rs. 703.6 Crs, marking a 19% year-over-year increase.
- Consolidated Profit After Tax (PAT) for Q1 FY27 stood at Rs. 50.1 Crs, a 7% decline YoY.
- Q1 FY26 PAT included a Rs. 15 Crs tax refund; excluding this, Q1 FY27 PAT grew 29% YoY.
- EBITDA for Q1 FY27 was Rs. 96.9 Crs, up 30% YoY, with EBITDA margin expanding 120 bps to 13.8%.
- Specialty Chemicals segment revenue grew 150% YoY to Rs. 82.6 Crs in Q1 FY27.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Total Revenue (Consolidated)
703.6 Rs. Crs.
19%
Gross Profit (Consolidated)
276.0 Rs. Crs.
27%
EBITDA (Consolidated)
96.9 Rs. Crs.
30%
EBITDA Margin % (Consolidated)
13.8%
120 bps
Profit Before Tax (PBT) (Consolidated)
69.2 Rs. Crs.
35%
Profit After Tax (PAT) (Consolidated)
50.1 Rs. Crs.
-7%
API Segment Revenue
510.4 Rs. Crs.
11%
Formulation Segment Revenue
86.2 Rs. Crs.
7%
Specialty Chemicals Segment Revenue
82.6 Rs. Crs.
150%
🏢 How This Affects the Company
Consolidated revenue growth of 19% YoY indicates increased sales volume and improved realizations across API and Specialty Chemicals portfolios. The 150% YoY growth in Specialty Chemicals segment revenue contributes to diversification.
Consolidated EBITDA increased 30% YoY to Rs. 96.9 Crs, with margin expansion of 120 bps, suggesting improved operational efficiency. However, Q1 FY27 PAT of Rs. 50.1 Crs was 7% lower YoY due to a Rs. 15 Crs tax refund in Q1 FY26.
The Sayakha facility operated at nearly 65% utilization, contributing to backward integration. Planned expansion of oral solid dosage (OSD) capabilities in Baddi is expected to double production capacity.
👥 What This Means For Shareholders
✅
Action Required
No action required from shareholders based on this financial results press release.
👤
Who Is Affected
All shareholders are affected by the company's financial performance. Consolidated PAT of Rs. 50.1 Crs translates to an EPS of Rs. 5.49 for Q1 FY27.
🔍
Management Signal
Management is focused on volume growth, improved realizations, operational efficiencies, product mix optimization, and capacity expansion in Baddi and Sayakha.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Monitor Q2 FY27 financial results for sustained revenue and margin growth.
Track progress of OSD capacity expansion in Baddi, Himachal Pradesh.
Observe utilization levels and contribution from the Sayakha facility.
LOW RISK
The filing indicates strong operational performance and strategic capacity expansion with limited immediate risks.
💡 Investor Takeaway
Aarti Drugs reported Q1 FY27 consolidated revenue of Rs. 703.6 Crs, up 19% YoY, and EBITDA of Rs. 96.9 Crs, up 30% YoY with 13.8% margin. Consolidated PAT decreased 7% YoY to Rs. 50.1 Crs, primarily due to a Rs. 15 Crs tax refund in Q1 FY26.
⚖️ Strengths & Concerns
✅ Positives
- Consolidated Total Revenue increased by 19% YoY to Rs. 703.6 Crs in Q1 FY27, reflecting sales growth.
- EBITDA grew by 30% YoY to Rs. 96.9 Crs in Q1 FY27, with EBITDA Margin % expanding by 120 bps to 13.8%.
⚠️ Concerns
- Consolidated Profit After Tax (PAT) decreased by 7% YoY to Rs. 50.1 Crs in Q1 FY27, compared to Rs. 54.0 Crs in Q1 FY26.
- The decline in PAT is attributed to Q1 FY26 including a principal tax refund of approximately Rs. 15 Crs.
📅 Company Track Record
Aarti Drugs reported Q1 FY27 consolidated profit of Rs. 5,013 lakhs and standalone profit of Rs. 5,085 lakhs in the July 31, 2026, filing. In Q1 FY27, consolidated revenue was Rs. 70,278 lakhs. The company reported FY26 Consolidated Profit of Rs. 19,494 lakhs.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Aarti Drugs' consolidated revenue for Q1 FY27?
Aarti Drugs reported consolidated total revenue of Rs. 703.6 Crs for the quarter ended June 30, 2026, marking a 19% increase year-over-year.
What was Aarti Drugs' consolidated Profit After Tax (PAT) in Q1 FY27?
The consolidated Profit After Tax (PAT) for Aarti Drugs in Q1 FY27 was Rs. 50.1 Crs, which is a 7% decrease compared to Rs. 54.0 Crs in Q1 FY26.
Why did Aarti Drugs' Q1 FY27 PAT decrease year-over-year?
The Q1 FY27 PAT decreased year-over-year because the Q1 FY26 PAT included a principal tax refund of approximately Rs. 15 Crs. Excluding this refund, the Q1 FY27 PAT would have shown a 29% YoY growth.
What was the growth in Aarti Drugs' EBITDA for Q1 FY27?
Aarti Drugs' consolidated EBITDA increased by 30% YoY to Rs. 96.9 Crs in Q1 FY27, with the EBITDA margin expanding by 120 bps to 13.8%.
How did the Specialty Chemicals segment perform for Aarti Drugs in Q1 FY27?
The Specialty Chemicals segment revenue for Aarti Drugs in Q1 FY27 was Rs. 82.6 Crs, showing a significant growth of 150% year-over-year.
Questions based on this BSE filing only. For information purposes.